ENOCHIAN BIOSCIENCES INC (ENOB) Stock Price, Quote, News and Overview
NASDAQ:ENOB - Nasdaq - US29350E1047 - Common Stock - Currency: USD
ENOB Quote, Performance and Key Statistics
0.7
0 (0%)
The current stock price of ENOB is 0.7 USD. In the past month the price increased by 47.99%. In the past year, price decreased by -75.52%.
ENOB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ENOB
Company Profile
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
Company Info
ENOCHIAN BIOSCIENCES INC
Century City Medical Plaza, 2080 Century City East
Los Angeles CALIFORNIA 90067 US
CEO: Mark Dybul
Employees: 11
Company Website: https://enochianbio.com/
Phone: 14539179840.0
ENOCHIAN BIOSCIENCES INC / ENOB FAQ
What is the stock price of ENOCHIAN BIOSCIENCES INC today?
The current stock price of ENOB is 0.7 USD.
What is the ticker symbol for ENOCHIAN BIOSCIENCES INC stock?
The exchange symbol of ENOCHIAN BIOSCIENCES INC is ENOB and it is listed on the Nasdaq exchange.
On which exchange is ENOB stock listed?
ENOB stock is listed on the Nasdaq exchange.
What is ENOCHIAN BIOSCIENCES INC worth?
ENOCHIAN BIOSCIENCES INC (ENOB) has a market capitalization of 40.80M USD. This makes ENOB a Nano Cap stock.
How many employees does ENOCHIAN BIOSCIENCES INC have?
ENOCHIAN BIOSCIENCES INC (ENOB) currently has 11 employees.
What are the support and resistance levels for ENOCHIAN BIOSCIENCES INC (ENOB) stock?
ENOCHIAN BIOSCIENCES INC (ENOB) has a resistance level at 0.71. Check the full technical report for a detailed analysis of ENOB support and resistance levels.
Should I buy ENOCHIAN BIOSCIENCES INC (ENOB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ENOB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ENOB, evaluating the profitability, health, valuation and growth aspects
- ENOCHIAN BIOSCIENCES INC (ENOB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ENOCHIAN BIOSCIENCES INC (ENOB) Sales and EPS estimates to see what analysts future expectations are.
- ENOCHIAN BIOSCIENCES INC (ENOB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ENOCHIAN BIOSCIENCES INC (ENOB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ENOCHIAN BIOSCIENCES INC (ENOB) Stock Chart to make your own analysis
- ENOCHIAN BIOSCIENCES INC (ENOB) Latest news and press-releases to stay up to date.
Does ENOCHIAN BIOSCIENCES INC (ENOB) stock pay dividends?
ENOB does not pay a dividend.
When does ENOCHIAN BIOSCIENCES INC (ENOB) report earnings?
ENOCHIAN BIOSCIENCES INC (ENOB) will report earnings on 2022-12-13, after the market close.
What is the Price/Earnings (PE) ratio of ENOCHIAN BIOSCIENCES INC (ENOB)?
ENOCHIAN BIOSCIENCES INC (ENOB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2).
ENOB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ENOB. When comparing the yearly performance of all stocks, ENOB is a bad performer in the overall market: 96.77% of all stocks are doing better.
ENOB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENOB. Both the profitability and financial health of ENOB have multiple concerns.
ENOB Financial Highlights
Over the last trailing twelve months ENOB reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -149.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |